Basic Information

Strain name
C57BL/6-Pdcd1tm1(PDCD1) Cd274tm1(CD274)Havcr2tm1(HAVCR2)/Bcgen
Common Name
B-hPD-1/hPD-L1/hTIM3 mice
Background
C57BL/6
Catalog number
130574
Related genes
PD-1 (Programmed death-1); CD274 (CD274 antigen); TIM3 (T-cell immunoglobulin and mucin domains-containing protein 3)

Description

PD-1 (Programmed death-1) is mainly expressed on the surface of T cells and primary B cells. The two PD-1 ligands, PD-L1 and PD-L2, are widely expressed on antigen-presenting cells (APCs). PD-1 interacts with its ligands and plays an important role in the negative regulation of the immune response. PD-L1 protein expression is detected in many human tumor tissues. PD-L1 expression in tumor cells could be induced by the microenvironment of tumor cells. PD-L1 expression is favorable for tumorigenesis and growth, for induction of anti-tumor T Cell Apoptosis, and for escaping responses by the immune system. Inhibition of PD-1 binding to its ligand can result in tumor cells that are exposed to the killing version of the immune system, and thus is a target for cancer treatments. PD-L1 (Programmed cell death ligand-1), also known as B7-H1 and CD274, is mainly expressed in antigen-presenting cells (APCs) and activated T cells, and is one of the two ligands of PD-1. The interaction between PD1 and PD-L1 plays an important role in the negative regulation of the immune response. PD-L1 is highly expressed in a variety of solid tumors. PD-1 and PD-L1 interactions can reduce T Cell Activation and promote tumor immune escape. The PD-1/PD-L1 signaling pathway can be blocked and antitumor immune response can be restored by using by anti-PD-1 or anti-PD-L1 antibodies to block the binding of PD1 to PD-L1. T-cell immunoglobulin domain and mucin domain-3 (TIM3) is an activation-induced inhibitory molecule involved in immune tolerance and T-cell exhaustion in chronic viral infection and cancers. TIM3 maturation and cell surface expression is facilitated by forming a heterodimeric interaction with CD66a. Co-blockade of CD66a and TIM3 enhanced anti-tumor immune responses, and eliminated tumors in mouse colorectal cancer models.

Targeting Strategy

Gene targeting strategy of B-hPD-1/hPD-L1/hTIM3 mice.The targeting strategy of B-hPD-1 mice is to the exon 2 of mouse PD-1 gene that encode the extracellular domain were replaced by human PD-1 exon 2. The targeting strategy of B-hPD-L1 mice is to the exon 3 of mouse PD-L1 gene that encode the extracellular domain were replaced by human PD-L1 exon 3. The targeting strategy of B-hTIM3 mice is to the exon 2 of mouse Tim3 gene that encode the extracellular domain were replaced by human TIM3 exon 2 . The B-hPD-1/hPD-L1/hTIM3 three knock-in model, was developed by breeding the B-hPD-1 mice, the B-hPD-L1 mice and the B-hTIM3 mice, has a functional mouse immune system.

Details

Protein expression analysis

Strain specific PD-1 expression analysis in homozygous B-hPD-1/hPD-L1/hTIM3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hPD-L1/hTIM3 (H/H) mice after stimulation with anti-CD3ε in vivo and without stimulation, and analyzed by flow cytometry with species-specific anti-PD-1 antibody. Mouse PD-1 was detectable in WT mice. Human PD-1 was exclusively detectable in homozygous B-hPD-1/hPD-L1/hTIM3 but not WT mice. After anti-CD3ε stimulation, hPD-1 protein expression was significantly increased.

Strain specific PD-L1 expression analysis in homozygous B-hPD-1/hPD-L1/hTIM3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hPD-L1/hTIM3 (H/H) mice after stimulation with anti-CD3ε in vivo and without stimulation, and analyzed by flow cytometry with species-specific anti-PD-L1 antibody. Mouse PD-L1 was detectable in WT mice. Human PD-L1 was exclusively detectable in homozygous B-hPD-1/hPD-L1/hTIM3 but not WT mice. After anti-CD3ε stimulation, hPD-L1 protein expression was significantly increased.

Strain specific TIM3 expression analysis in homozygous B-hPD-1/hPD-L1/hTIM3 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hPD-L1/hTIM3 (H/H) mice after stimulation with anti-CD3ε in vivo and without stimulation, and analyzed by flow cytometry with species-specific anti-TIM3 antibody. Mouse TIM3 was detectable in WT mice. Human TIM3 was exclusively detectable in homozygous B-hPD-1/hPD-L1/hTIM3 but not WT mice. After anti-CD3ε stimulation, hTIM3 protein expression was significantly increased.

Analysis of Blood leukocytes cell subpopulations –No anti-mCD3

Analysis of Spleen leukocytes cell subpopulations –No anti-mCD3

Analysis of Spleen leukocytes cell subpopulations – anti-mCD3

Analysis of lymph node leukocytes cell subpopulations

Analysis of blood,spleen and lymph node leukocytes cell subpopulations

Analysis of blood,spleen and lymph node leukocytes cell subpopulations by FACS Blood, spleen and lymph node leukocytes cell were isolated from female mice in the panel(n=3, 6 week-old). Flow cytometry analysis was performed to assess leukocyte subpopulations. Percent of T, B, NK, Granulocytes, Monocyte, DC and macrophage cells in homozygous B-hPD-1/hTIM3、 B-hPD-1/hPD-L1/hTIM3 mice were similar to those in the C57BL/6 mice both at rest and in stimulated with anti-CD3ε in vivo, demonstrating that the humanized mouse does not change the overall development, differentiation or distribution of these cell types in blood,spleen and lymph node.

Analysis of blood T cell subpopulations

Analysis of spleen T cell subpopulations

Analysis of lymph node T cell subpopulations

Analysis of blood,spleen and lymph node T cell subpopulations

Analysis of blood,spleen and lymph node T cell subpopulations by FACS Blood, spleen and lymph node leukocytes cell were isolated from female mice in the panel(n=3, 6 week-old). Flow cytometry analysis was performed to assess leukocyte subpopulations. Percent of CD4+T, CD8+T and Treg cells in homozygous B-hPD-1/hTIM3、B-hPD-1/hPD-L1/hTIM3 mice were similar to those in the C57BL/6 mice both at rest and in stimulated with anti-CD3ε in vivo, demonstrating that the humanized mouse does not change the overall development, differentiation or distribution of these cell types in blood,spleen and lymph node.

Combination therapy of anti-human PD-L1 antibody and anti-human TIM3 antibody

Antitumor activity of anti-human PD-L1 Atezolizumab (in house) combined with anti-human TIM3 antibody in B-hPD-1/hPD-L1/hTIM3 mice. (A) Anti-human PD-L1 antibody combined with anti-human TIM3 antibody inhibited B-CAG-hPD-L1 MC38 tumor growth in B-hPD-1/hPD-L1/hTIM3 mice. Murine colon cancer B-CAG-hPD-L1 MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hTIM3 mice (female, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with atezolizumab (in house) and anti-human TIM3 antibody with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-L1 antibody and anti-human TIM3 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hTIM3 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hPD-L1 antibodies and hTIM3 antibodies. Values are expressed as mean ± SEM.

Combination therapy of anti-human PD-1 antibody and anti-human TIM3 antibody

Antitumor activity of anti-human PD-1 Keytruda (in house) combined with anti-human TIM3 antibody in B-hPD-1/hPD-L1/hTIM3 mice. (A) Anti-human PD-1 antibody combined with anti-human TIM3 antibody inhibited B-CAG-hPD-L1 MC38 tumor growth in B-hPD-1/hPD-L1/hTIM3 mice. Murine colon cancer B-CAG-hPD-L1 MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hTIM3 mice (female, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with Keytruda (in house) and anti-human TIM3 antibody with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of anti-human PD-1 antibody and anti-human TIM3 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hPD-L1/hTIM3 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hPD-1 antibodies and hTIM3 antibodies. Values are expressed as mean ± SEM.